Arjan Narbad

Group Leader

Quadram institute Bioscience

NORWICH, United Kingdom

6 profile visitsResearch

I am a microbiologist with interest in developing probiotics, bacteriotherapy and fermented foods for modulation of the gut microbiome for health benefits.

My organisation

Quadram institute Bioscience

Quadram institute Bioscience

Research - Research Institute

NORWICH, United Kingdom

At Quadram Institute Bioscience, we are a diverse team of scientists and experts dedicated to advancing our understanding of food, health, and disease. Our cutting-edge research focuses on the gut microbiome and its impact on human health, as well as developing innovative solutions to address global health challenges. We collaborate with industry partners, academic institutions, and health organizations to translate our findings into real-world applications. Together, we aim to drive scientific innovation and improve health outcomes for communities around the globe.
Read more

About me

Arjan Narbad

arjan.narbad@quadram.ac.uk

Arjan Narbad - Quadram Institute

Current Employment

Group Leader: Translational Microbiome Group, Quadram Institute Bioscience, Norwich, UK.

Honorary Professor: School of Biological Sciences, University of East Anglia, UK;

Visiting Professor: Jiangnan University, Wuxi, China.

Co-Director UK-China Joint Centre for Probiotics Research

I am leading the Translational Microbiome Research Group at QIB. My group is focused on both fundamental and applied research on the role of gut bacteria. Currently I am working on the translational aspects of gut bacteria as probiotics for exclusion and inhibition of pathogens and studying the impact of diet /gut bacteria interactions in the health and disease. My group is using molecular profiling methods, metabolomics and colon model systems to understand these complex interactions. We are using probiotics and bacteriotherapy for exclusion of gut pathogens in humans and animals and investigating the mechanism of competitive exclusion. My research is also focused on the development of novel strategies including probiotics, phage therapy, bacteriotherapy, endolysins and lantibiotics for biocontrol of the gut pathogens and for modulation of the gut microbiome for health benefits with focus on sulphate reducing bacteria. We are also implementing faecal microbiota transplantation bacteriotherapy for treatment of C. difficile infections in elderly patients. We are also interested in functional fermented foods and development of starter cultures

Social media